Efficacy of temozolomide therapy in patients with aggressive pituitary adenomas and carcinomas - a German survey.
Despite growing evidence that temozolomide (TMZ) therapy is effective for the treatment of aggressive pituitary tumours (APT) or carcinomas (PC), individual therapy decisions remain challenging. We therefore aimed to report on clinical characteristics leading to initiation of TMZ therapy and to add evidence on TMZ long-term effectiveness. Retrospective survey on TMZ treatment in patients with APT or PC. TMZ therapy was initiated in 47 patients (22 females) with APT (n=34) or PC (N=13). Mean age at diagnosis was 45±15 years. The immunohistochemical subtypes were corticotroph (n=20), lactotroph (n=18) and non-functioning (n=9) tumours. TMZ therapy started 8 years after initial diagnosis using a standard regimen (median 6 cycles) for the majority of patients. Long-term radiological response to TMZ after a median follow-up of 32 months with 4 patients still on TMZ therapy was tumour regression for 9 (20%), stable disease for 8 (17%), and tumour progression for 29 patients (63%) (outcome data available for 46 patients). Progression occurred 16 months after initiation of TMZ. Median estimated progression-free survival was 23 months. Disease stabilisation and median progression-free survival did not differ between patients with APT or PC. Predictors of tumour response were not identified. Overall, TMZ was well-tolerated. We performed a nation-wide survey on TMZ therapy in patients with APT and PC. While early response rates to TMZ are promising, long-term outcome is less favourable. Prolonged TMZ administration should be considered. We were not able to confirm previously reported predictors of tumour response to TMZ.